The future of cardiac disease assessment using 18F-FDG PET/CT (original) (raw)

This paper discusses the role of 18F-FDG PET/CT in the assessment of cardiac diseases, particularly focusing on its application in diagnosing coronary artery disease and cardiac sarcoidosis. The metabolic properties of 18F-FDG, especially its uptake in myocardial cells, are explored in the context of different cardiac conditions, emphasizing the need for specific preconditions such as fasting and glucose loading to distinguish between normal physiological uptake and pathological patterns. The findings aim to enhance the accuracy in evaluating myocardial viability and inflammation, paving the way for improved diagnostic standards in nuclear cardiology.